共 25 条
[1]
Vaughan W.P., Civin C.I., Weisenburger D.D., Karp J.E., Graham M.L., Sanger W.G., Grierson H.L., Joshi S.S., Burke P.J., Acute leukemia expressing the normal human hemopoietic stem cell membrane glycoprotein CD34 (My 10), Leukemia, 2, pp. 661-666, (1988)
[2]
Borowtiz M.J., Gockerman J.P., Moore J.O., Civin C.I., Page S.O., Robertson J., Bigner S.H., Clinicopathologic and cytogenetic features of CD 34 (My 10)-positive acute nonlymphocytic leukemia, Am. J. Clin. Pathol., 91, pp. 2-270, (1989)
[3]
Campos L., Guyotat D., Archimbaud E., Devaux Y., Treille D., Larese A., Maupas J., Gentilhomme O., Ehrsam A., Fiere D., Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy, Br. J. Haematol., 72, pp. 161-166, (1989)
[4]
Geller R.B., Zahurak M., Hurwitz C.A., Burcke P.J., Karp J.E., Piantadosi S., Civin C.I., Prognostic importance of immunotyping in adults with acute myelocytic leukemia: the significance of the stem-cell glycoprotein CD34 (My10), Br. J. Haematol., 76, pp. 340-347, (1990)
[5]
Guinot M., Sanz G.F., Sempere A., Arilla M.G., Jarque I., Gomis F., Sanz M.A., Prognostic value of CD34 in de novo acute myeloblasts leukemia, Br. J. Haematol., 78, pp. 533-534, (1991)
[6]
Lee E.J., Yang J., Leavitt R.D., Testa J.R., Civin C.I., Forrest A., Schiffer C.A., The significance of CD34 and TdT determination in patients with untreated de novo Acute myeloid leukemia, Leukemia, 6, pp. 1203-1209, (1992)
[7]
Solary E., Casasnovas R.O., Campos L., Bene M.C., Faure G., Maingon P., Falkenrodl A., Lenormand B., Genetet N., Surface markers in adult myeloblasts leukemia: correlation of CD19+, CD34+, and CD14+/DR-phenotypes with shorter survival, Leukemia, 6, pp. 393-399, (1992)
[8]
Holowiecki J., Lutz D., Krzemien S., Stella-Holowiecka B., Graf F., Kelenyi G., Schranz V., Callae V., Brugiatelli M., Neri A., Magyarlaki T., Ihle R., Jagoda K., Rudzka E., CD 15 antigen detected by the VIM-D5 monoclonal antibody for prediction of ability to achieve complete remission in acute nonlymphocytic leukemia, Acta Haematol., 76, pp. 16-19, (1986)
[9]
Schwarzinger I., Valent P., Koller U., Marosi C., Schneider B., Haas O., Knapp W., Lechner K., Bettelheim P., Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia, J. Clin. Oncol., 8, pp. 423-430, (1990)
[10]
Griffin J.D., Davis R., Nelson D.A., Davey F.R., Mayer R.J., Schiffer C., McIntyre O.R., Bloomfield C.D., Use of surface marker analysis to predict outcome of adult myeloblastic leukemia, Blood, 68, pp. 1232-1241, (1986)